To Top


Philippines holds a bright future for players in the pharmaceutical industry. Economic as well as population growth makes the country’s pharmaceutical market supremely attractive in the ASEAN region.

Philippines is the third-largest pharmaceutical market in ASEAN and it is worth $4 billion in 2019 (IQVIA March 2019 MAT).

Alkem started its operations in the country through its fully owned subsidiary, Alkem Laboratories Corporation in July 2011. We have started with focus on Pulmonology, Gastroenterology and Gynaecology. We intend to strengthen our presence in these segments through new launches in short to medium term. Over a longer term, we will foray into chronic segments such as Cardiology and Urology.

We focus strongly on the prescription sales, which constitutes to 80% of our revenues. These sales are driven by a robust team of MRs and managers.

Contact Us :

Alkem Laboratories Corporation

5/F Filipino Building, 135 Dela Rosa cor.
Legaspi and Bolanos, Legaspi village,
Makati, Metro Manila.
E-mail ID:

Adverse Event Reporting

Pharmacovigilance Officer: Maricar Lim
Contact Number: (02) 8845-0653 loc 103
Email address: